ADELAIDE, Australia / RankWire.AI / – In the ongoing fight against aggressive breast cancers, Australian scientists have uncovered a molecular mechanism that influences tumor metastasis, potentially paving the way for innovative treatment strategies aimed at preventing secondary tumor formation. Published in EMBO Molecular Medicine, research conducted by teams from Adelaide University and the Olivia Newton-John Cancer Research Institute revealed that boosting levels of a crucial regulatory molecule called miR-342 can significantly limit the spread of tumors. The study highlights a promising approach to combat triple-negative breast cancer by targeting quiescent cancer cells before they develop into dangerous metastases in distant organs.
This subtype of breast cancer, which constitutes 10% to 15% of Australia’s roughly 21,000 new cases annually, is responsible for a disproportionately high number of fatalities. Characterized by the absence of estrogen, progesterone, and HER2 receptors, it does not respond to standard hormone-targeted treatments. The research team showed that when miR-342 levels decrease, a cancer-promoting pathway known as E2F becomes excessively active, facilitating the dissemination of dormant cancer cells and the formation of lethal secondary tumors.
Targeted Treatment Strategies Bring New Hope for Preventing Metastasis in High-Risk Patients
In laboratory models, scientists demonstrated that restoring miR-342 expression markedly impeded the migration of cancer cells to distant sites. Moreover, they found that palbociclib, an already-approved CDK4/6 inhibitor used for hormone receptor-positive breast cancers, effectively suppressed metastatic tumor growth in models with reduced miR-342 levels. These results suggest that assessing miR-342 levels could help clinicians repurpose existing drugs for treating patients at elevated risk of metastasis.
Associate Professor Philip Gregory, co-senior author from the Centre for Cancer Biology at Adelaide University, emphasized that metastasis prevention remains the foremost challenge in managing aggressive breast cancers. He highlighted that because palbociclib inhibits the overactive E2F pathway, its administration after cancer cells have spread can prevent microscopic deposits from enlarging. This therapeutic strategy shifts focus from merely shrinking primary tumors to halting the progression of microscopic secondary cancers that could become life-threatening.
Pre-Clinical Research Published in the Peer-Reviewed EMBO Molecular Medicine
The researchers acknowledged that the biological diversity of triple-negative breast cancer has historically challenged the development of universal targeted therapies. By identifying a specific biological vulnerability shared by a particular patient subgroup, this study opens avenues for tailored treatment options. As Australian scientists continue exploring new approaches, efforts are underway to validate these findings using patient-derived models in preparation for clinical trials.
Cancer specialists and research organizations across Australia expressed optimism regarding these results, stressing the critical need for broader therapeutic choices when primary treatments fall short. The research team intends to work with international clinical networks to accelerate protocols for biomarker screening. Confirming the effectiveness of miR-342 testing could soon enable clinicians to identify suitable candidates for early intervention with targeted CDK4/6 inhibitor therapies.